Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Protalix Biotherapeutics (PLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 115,441
  • Shares Outstanding, K 124,130
  • Annual Sales, $ 9,200 K
  • Annual Income, $ -29,370 K
  • 36-Month Beta 0.73
  • Price/Sales 13.49
  • Price/Cash Flow 0.00
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.27
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/08/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.90 +3.33%
on 04/28/17
1.40 -33.57%
on 04/11/17
-0.31 (-25.00%)
since 03/28/17
3-Month
0.60 +55.00%
on 01/31/17
1.51 -38.41%
on 03/14/17
+0.31 (+50.00%)
since 01/27/17
52-Week
0.26 +257.69%
on 12/13/16
1.51 -38.41%
on 03/14/17
+0.09 (+10.71%)
since 04/28/16

Most Recent Stories

More News
Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase(TM)) for the Treatment of Cystic Fibrosis

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive results from the Company's phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF). Sixteen...

PLX : 0.93 (-7.00%)
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?

Options traders are pricing in a big move for Protalix BioTherapeutics (PLX) shares as it has huge implied volatility

PLX : 0.93 (-7.00%)
Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight

NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The Biotech Sector is seeing the arrival of some new competitors, with one company continuing to overperform and another set to have its business absorbed or...

CERU : 0.56 (-8.20%)
PLX : 0.93 (-7.00%)
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.93 (-7.00%)
Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium(TM) 2017

Data to be presented in three oral presentations and two poster presentations

PLX : 0.93 (-7.00%)
Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%

Protalix BioTherapeutics, Inc. (PLX)was a big mover last session, as the company saw its shares rise nearly 12% on the day.

PLX : 0.93 (-7.00%)
SNSS : 3.87 (+4.31%)
Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase(TM)) for the Treatment of Cystic Fibrosis

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim results from the Company's phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF)...

PLX : 0.93 (-7.00%)
Blog Coverage Protalix Receives Letter Intending Purchase of Alfataliglicerase to Treat Gaucher Patients in Brazil

Upcoming AWS Coverage on Forward Pharma Post-Earnings Results

PLX : 0.93 (-7.00%)
FWP : 19.73 (+2.23%)
Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the "Company") announced today that the Company received a letter from Fundacão Oswaldo Cruz (Fiocruz), an arm of the Brazilian Ministry of...

PLX : 0.93 (-7.00%)
Protalix BioTherapeutics (PLX) Jumps: Stock Rises 14.3%

Protalix BioTherapeutics, Inc. (PLX) moved big last session, as its shares jumped a little over 14% on the day.

PLX : 0.93 (-7.00%)
VNDA : 15.25 (+0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant...

See More

Support & Resistance

2nd Resistance Point 1.04
1st Resistance Point 0.99
Last Price 0.93
1st Support Level 0.89
2nd Support Level 0.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.